MedTrace Logo

COVID-19 Methylene Blue Antiviral Treatment

NCT05004805 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-02-09

No results posted yet for this study

Summary

This is a pilot study of a single-center, blind, randomized, placebo-controlled, parallel-group study testing for the efficacy and safety of Methylene blue when administered topically as a 0.02% solution for nasopharyngeal and oropharyngeal irrigation in COVID-19 patients requiring hospitalization.

Conditions

  • Covid19

Interventions

DRUG

Methylene Blue

MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.

DRUG

Saline nasal spray

Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.

Sponsors & Collaborators

  • Irkutsk State Medical University

    collaborator OTHER

  • Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-06
Primary Completion
2021-12-12
Completion
2021-12-12

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05004805 on ClinicalTrials.gov